Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.

Authors :: Zwimpfer TA
Ewald H
Bilir E
Jayawardana M
Appenzeller-Herzog C
Bizzarri N
Razumova Z
Kacperczyk-Bartnik J
Heinzelmann-Schwarz V
Friedlander M
Bowtell DD
Garsed DW
Source :: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2024 Sep 23; Vol. 9. Cochrane AN: CD015896. Date of Electronic Publication: 2024 Sep 23.
Publication Year :: 2024
Abstract: Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.<br /> (Copyright © 2024 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)

Subjects :: Humans
Female
Fallopian Tube Neoplasms genetics
Fallopian Tube Neoplasms mortality
Fallopian Tube Neoplasms pathology
Fallopian Tube Neoplasms drug therapy
Cystadenocarcinoma, Serous genetics
Cystadenocarcinoma, Serous mortality
Prognosis
Progression-Free Survival
Genes, BRCA2
Genes, BRCA1
Mutation
Ovarian Neoplasms genetics
Ovarian Neoplasms mortality

Full Text Access

Tools